Home Tags Site specific conjugation

Tag: site specific conjugation

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
Photo: Exhibition - Bird's Eye Overview. The 15th annual PEGS: The Essential Protein Engineering Summit brought more than 2,700 world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions to the Seaport World Trade Center in Boston, MA this past April 8-12, 2019, setting record-breaking attendance. Photo courtesy: CHI/PEGS

PEGS: Novel Technology to Enhance Cell Line Productivity and Expand the...

During the 16th Annual PEGS Boston Virtual Conference & Expo, which took place between August 31 – September 4, 2020, Gregory Bleck, Ph.D., Global...

BrickBio’s Novel Therapeutic Conjugation Platform Validated at Commercial Scale

Boston-based BrickBio has demonstrated its ability to insert unnatural amino acids (UAAs; called "attachment bricks"), at any site, specifically, within a protein or antibody...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
HPAPI Lab at Abzena. Photo Courtesy: 2019 Abzena.

Addressing the Challenges of Bioconjugate Medicines

The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...

New ADC Payload Platform – Synaffix Launches toxSYN™

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

PEGG 2017: RESPECT Antibody-drug Conjugate Technology

Earlier this year, a record number of 2,300 delegates attended the 13th edition of the "PEGS: The Essential Protein Engineering Summit," held May 1...

Selenomab-drug Conjugates: Delivering Strong Results in Treating Cancers

Scientists from the Florida campus of The Scripps Research Institute (TSRI), one of the world's largest independent, not-for-profit organizations focusing on research in the...

Antibody-drug conjugates: Recent Advances in Conjugation and Linker Chemistries

Authors: Tsuchikama K , An Z Title: Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Published in: Protein Cell. 2016 Oct 14.Keywords: antibody-drug conjugates; cancer;...

Site-specific Conjugation Based on Bacterial Transglutaminase Shows Improved Therapeutic Index of...

The key conclusion of these posters is that ADCs generated by BTG-ADC have improved pharmacokinetics and show a beter therapeutic index in in vivo models compared to brentuximab, with a significantly higher maximum tolerated dose (>60mg/kg vs 18 mg/kg) and a higher specific tumoral uptake.